DVAX and VXRT Related Headlines
Go Back- Dynavax reports Q3 revenue growth and authorizes $100M share buyback
- Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program
- Dynavax licenses Vaxart's oral COVID-19 vaccine for $25 million upfront
- Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program
DVAX and VXRT Related Press Releases
Go Back- Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program
- Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program
